Immune profiling analysis of double-negative T cells in patients with systemic sclerosis.

OBJECTIVE: To construct a molecular immune map of patients with systemic sclerosis (SSc) by mass flow cytometry, and compare the number and molecular expression of double-negative T (DNT) cell subsets between patients and healthy controls (HC). METHODS: Peripheral blood mononuclear cells (PBMCs) were extracted from the peripheral blood of 17 SSc patients and 9 HC. A 42-channel panel was set up to perform mass cytometry by time of flight (CyTOF) analysis for DNT subgroups. Flow cytometry was used to validate subpopulation functions. The clinical data of patients were collected for correlation analysis. RESULTS: Compared with HC, the number of total DNT cells decreased in SSc patients. Six DNT subsets were obtained from CyTOF analysis, in which the proportion of cluster1 increased, while the proportion of cluster3 decreased. Further analysis revealed that cluster1 was characterized by high expression of CD28 and CCR7, and cluster3 was characterized by high expression of CD28 and CCR5. After in vitro stimulation, cluster1 secreted more IL-4 and cluster3 secreted more IL-10 in SSc patients compared to HC. Clinical correlation analysis suggested that cluster1 may play a pathogenic role while cluster3 may play a protective role in SSc. ROC curve analysis further revealed that cluster3 may be a potential indicator for determining disease activity in SSc patients. CONCLUSION: We found a new CCR5+CD28+ DNT cell subset, which played a protective role in the pathogenesis of SSc. Key Points • The number of DNT cells decreased in SSc patients' peripheral blood. • DNT cells do not infiltrate in the skin but secrete cytokines to participate in the pathogenesis of SSc. • A CCR5+CD28+ DNT cell population may play a protective role in SSc.

Hypothyroidism is a causal determinant of age-related cataract risk in European population: a Mendelian randomization study.

Objective: To determine whether there is a causal relationship between thyroid dysfunction and the risk of age-related cataract (ARC) in the European population. Design: A two-sample Mendelian randomization (MR) study. Methods: Hypothyroidism, hyperthyroidism, free thyroxine (fT4), and thyrotropin (TSH) were selected as exposures. The single nucleotide polymorphisms (SNP) of hypothyroidism and hyperthyroidism were obtained from the genome-wide association studies (GWAS) of the IEU database, including 337,159 subjects. Data for fT4 and TSH (72,167 subjects) were extracted from the ThyroidOmics Consortium. ARC was used as the outcome. The SNPs associated with ARC were selected from a GWAS of 216,362 individuals in the FinnGen database. The main method used was the inverse variance-weighted method, together with four complementary methods. Sensitivity analyses were performed using Cochran's Q test, MR-PRESSO, MR-Egger regression and leave-one-out test. MR pleiotropy was used to test for pleiotropy. MR Steiger test was used to test for the directionality. Results: Two-sample MR analysis revealed a positive association between genetically predicted hypothyroidism and risk of ARC (OR = 2.501, 95% CI: 1.325-4.720; P = 0.004). Hyperthyroidism, circulating fT4 and TSH levels did not have a significant causal effect on ARC (P > 0.05). The results were robust and reliable, and no horizontal pleiotropy was found after sensitivity analyses. In the MR Steiger test, we found no reverse causal effects of hypothyroidism on the ARC (P <0.001). Conclusions: Our study provides strong evidence that hypothyroidism is a causal determinant of ARC risk.

Constructing Acrylic-Bonded Stationary Phase as an Artificial SEI for Highly Stable Zn Metal Anodes.

The development of aqueous zinc-ion batteries (AZIBs) has been severely restricted by metallic Zn anode issues, including Zn dendrites and uncontrollable side reactions. The direct interfacial modification of a Zn anode is a facile and effective strategy that has been favored by researchers. Herein, we propose an acrylic-bonded stationary layer as an artificial solid electrolyte interface (SEI) for the Zn anode to manipulate the Zn plating/stripping. The constructed modification layer is made of zinc acrylate cross-linked to form a three-dimensional (3D) porous structure, which can induce uniform deposition of zinc ions and balance the local electric field, thus achieving homogeneous nucleation and uniform Zn deposition. More importantly, this fabricated layer is chemically bonded to the zinc surface and can tolerate prolonged zinc deposition without shedding compared with conventional physical coatings. Consequently, the Zn/Zn symmetric cells, Zn/Na0.92V2O5·nH2O (NaVO) full cells, and Zn hybrid supercapacitors using this acrylic-bonded modified anode demonstrate greatly improved cycle performance.

Stem Cell Therapy in Lupus.

Systemic lupus erythematosus (SLE) is a chronic autoimmune and inflammatory disease with multiple organs and systems involved such as the kidney, lung, brain and the hematopoietic system. Although increased knowledge of the disease pathogenesis has improved treatment options, current immunosuppressive therapies have failed to prevent disease relapse in more than half of treated patients. Thus, the cell replacement therapy approach that aims to overcome adverse events of traditional treatment and improve recovery rate of refractory SLE is considered as an alternative treatment option. A large number of animal studies and clinical trials have shown stem cell therapy to be a promising therapeutic approach for the treatment of SLE. Since the first transplantation into human patients, several stem cell types have been applied in this field, including hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs). In this review, we overview different cell sources of stem cells and applications of the stem cell therapy for treatment of SLE, as well as the comparison between HSCs transplantation (HSCT) and MSCs transplantation (MSCT).

Bidirectional Interface Protection of a Concentrated Electrolyte, Enabling High-Voltage and Long-Life Aqueous Zn Hybrid-Ion Batteries.

Prussian blue analogues (PBAs) as a promising high-voltage cathode material for aqueous zinc-ion batteries (ZIBs) are usually subjected to an ephemeral lifespan and low Coulombic efficiency due to the irreversible phase change and high Zn2+ insertion potential. Besides, Zn dendrites, H2 evolution reaction, and corrosion derived from a Zn anode interface remain huge challenges. Given this, a highly stable zinc hexacyanoferrate (KZnHCF) cathode together with a mixed concentrated electrolyte is prepared to realize a high-voltage and long-life aqueous ZIB, in which the mixed concentrated electrolyte consisting of 30 m KFSI + 1 m Zn(CF3SO3)2 possesses a unique Zn2+ solvation sheath (Zn(CF3SO3)0.3(FSI)3.1(H2O)2.6) that can not only stabilize the cathode interface and improve the Coulombic efficiency but also fundamentally solve the Zn anode interface issues. As a result, the aqueous KZnHCF/Zn battery achieves an ultralong life over 3000 cycles without any capacity decay even under a high discharge voltage of 1.78 V (vs Zn2+/Zn). Such extraordinary performance represents significant progress in aqueous PBA-based ZIBs. This work shares guidance to improve the performance of aqueous ZIBs through optimizing the electrolyte in tuning the stable operation of the cathode and the zinc anode.

Biomolecular Regulation of Zinc Deposition to Achieve Ultra-Long Life and High-Rate Zn Metal Anodes.

Aqueous zinc-ion batteries (ZIBs) have been extensively studied due to their inherent safety and high energy density for large-scale energy storage. However, the practical application is significantly limited by the growing Zn dendrites on metallic Zn anode during cycling. Herein, an environmental biomolecular electrolyte additive, fibroin (FI), is proposed to guide the homogeneous Zn deposition and stabilize Zn anode. This work demonstrates that the FI molecules with abundant electron-rich groups (NH, OH, and CO) can anchor on Zn anode surface to provide more nucleation sites and suppress the side reactions, and the strong interaction with water molecules can simultaneously regulate the Zn2+ coordination environment facilitating the uniform deposition of Zn. As a consequence, only 0.5 wt% FI additive enables a highly reversible Zn plating/stripping over 4000 h at 1 mA cm-2 , indicating a sufficient advance in performance over state-of-the-art Zn anodes. Furthermore, when applied to a full battery (NaVO/Zn), the cell exhibits excellent capacity retention of 98.4% after 1000 cycles as well as high Coulombic efficiency of 99%, whereas the cell only operates for 68 cycles without FI additive. This work offers a non-toxic, low-cost, effective additive strategy to solve dendrites problems and achieve long-life and high-performance rechargeable aqueous ZIBs.

Iron phosphate hydroxide hydrate as a novel anode material for advanced aqueous full potassium-ion batteries.

The development of aqueous potassium-ion batteries is limited by the lack of suitable anode materials. Here, a novel anode material, iron phosphate hydroxide hydrate Fe1.19PO4(OH)0.18(H2O)0.3, was introduced and synthesized, which delivers considerable reversible capacities of 80 mA h g-1 at 0.05 A g-1. An aqueous full potassium-ion battery assembled with the K2Zn3(Fe(CN)6)2 cathode exhibits 80% capacity retention after 1000 cycles.

Low Concentration DMF/H2O Hybrid Electrolyte: A New Opportunity for Anode Materials in Aqueous Potassium-Ion Batteries.

Superconcentrated "water-in-salt" electrolytes have greatly widened the electrochemical stable window (ESW) of aqueous electrolytes, but they also generate new problems, including high costs, high viscosity, and low conductivity. Here we report a 2 m low concentration electrolyte using an N,N-dimethylformamide/water (DMF/H2O) hybrid solvent, which provides a wider ESW (2.89 V) than an aqueous electrolyte (2.66 V) and presents nonflammability, high conductivity, and low viscosity characteristics. In 2 m DMF/H2O hybrid electrolyte, the LUMO energy of the DMF solvent (-0.00931 a.u.) is lower than that of H2O (-0.00735 a.u.), which could effectively promote the degradation of FSI- and lead to stable solid electrolyte interphase formation. As a result, the electrochemical reversibility and cyclability of the KTi2(PO4)3@C (KTP@C) anode in the aqueous electrolyte have been significantly enhanced with the help of DMF addition. Moreover, the K2Zn3(Fe(CN)6)2 (KZnHCF)//KTP@C full potassium-ion battery exhibits highly efficient stability and rate capability with a long cycle performance over 10 000 cycles and delivers a specific discharge capacity of 33 mAh g-1 at a high current density of 20 A g-1. Low concentrations of DMF/H2O hybrid electrolytes can inhibit the hydrogen evolution reaction of aqueous electrolytes, providing more opportunities for the practical application of electrode materials. Not limited to DMF solvent, mixing organic and aqueous solvents will provide more available options and perspectives for improving the energy density and long cycle performance of the aqueous metal-ion battery.

High-Capacity Layered Magnesium Vanadate with Concentrated Gel Electrolyte toward High-Performance and Wide-Temperature Zinc-Ion Battery.

Aqueous zinc-ion batteries (ZIBs) have emerged as the most promising alternative energy storage system, but the development of a suitable cathode and the issues of Zn anodes have remained challenging. Herein, an effective strategy of high-capacity layered Mg0.1V2O5·H2O (MgVO) nanobelts together with a concentrated 3 M Zn(CF3SO3)2 polyacrylamide gel electrolyte was proposed to achieve a durable and practical ZIB system. By adopting the designed concentrated gel electrolyte which not only inherits the high-voltage window and wide operating temperature of the concentrated electrolyte but also addresses the Zn dendrite formation problem, the prepared cathode exhibits an ultrahigh capacity of 470 mAh g-1 and a high rate capability of 345 mAh g-1 at 5.0 A g-1, and the assembled quasi-solid-state ZIBs achieve 95% capacity retention over 3000 cycles as well as a wide operating temperature from -30 to 80 °C, demonstrating a promising prospect for large-scale energy storage. In situ X-ray diffraction, X-ray photoelectron spectroscopy, and thermogravimetric analysis (TGA) investigations also demonstrate a complex reaction mechanism for this cathode involving the (de)insertion of Zn2+, H+, and water molecules during cycling. The water molecules will reinsert into the interlayer and act as "pillars" to stabilize the host structure when Zn2+ is fully extracted.

Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients.

Allogeneic mesenchymal stem cells (MSCs) exhibit immunoregulatory function in human autoimmune diseases such as systemic lupus erythematosus (SLE), but the underlying mechanisms remain incompletely understood. Here we show that the number of peripheral tolerogenic CD1c+ dendritic cells (DCs) and the levels of serum FLT3L are significantly decreased in SLE patients especially with lupus nephritis, compared to healthy controls. Transplantation of allogeneic umbilical cord-derived MSCs (UC-MSCs) significantly up-regulates peripheral blood CD1c+DCs and serum FLT3L. Mechanistically, UC-MSCs express FLT3L that binds to FLT3 on CD1c+DCs to promote the proliferation and inhibit the apoptosis of tolerogenic CD1c+DCs. Conversely, reduction of FLT3L with small interfering RNA in MSCs abolishes the up-regulation of tolerogenic CD1c+DCs in lupus patients treated with MSCs. Interferon-γ induces FLT3L expression in UC-MSCs through JAK/STAT signaling pathway. Thus, allogeneic MSCs might suppress inflammation in lupus through up-regulating tolerogenic DCs.

Serum IFN-γ Predicts the Therapeutic Effect of Mesenchymal Stem Cells Transplantation in Systemic Lupus Erythematosus Patients.

Umbilical cord (UC)-derived mesenchymal stem cells (MSCs) show immunoregulatory properties on various immune cells and display therapeutic effects on various autoimmune diseases such as systemic lupus erythematosus (SLE). The aim of this study was to investigate the effect of the SLE environment on UC MSCs and to identify a potential serum biomarker to predict the therapeutic effect. UC MSCs were cocultured with peripheral blood mononuclear cells (PBMCs) from active lupus patients, and the proliferation, apoptosis and surface markers of UC MSCs were observed. UC MSC functional molecules were assessed by real-time polymerase chain reaction, and the signaling pathways were analyzed by Western blot. The clinical effect of MSC transplantation (MSCT) for lupus patients was followed-up, whereas baseline serum cytokines were analyzed by enzyme-linked immunosorbent assay. The coculture of PBMC from lupus patients promoted MSC proliferation. Lupus PBMCs were more potent in stimulating UC MSCs to secrete vascular endothelial growth factor (VEGF) and CXCL-12. Furthermore, lupus PBMCs activated Akt, IκB, and Stat5 signaling pathways in UC MSCs but did not affect Erk1/2 and Smad1/5/8 pathways. Moreover, our clinical study showed that higher baseline levels of IFN-γ might predict a good response to MSCT in active lupus patients. Baseline IFN-γ levels may predict clinical response to MSC therapy for active lupus patients, which will help to choose suitable patients for clinical transplantation. Stem Cells Translational Medicine 2017;6:1777-1785.

The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus.

BACKGROUND AND OBJECTIVE: Umbilical cord (UC)-derived mesenchymal stem cells (MSCs) have shown immunoregulation of various immune cells. The aim of this study was to investigate the mechanism of UC MSCs in the regulation of peripheral regulatory T cells (Treg) and T helper 17 (Th17) cells in patients with systemic lupus erythematosus (SLE). METHODS: Thirty patients with active SLE, refractory to conventional therapies, were given UC MSCs infusions. The percentages of peripheral blood CD4+CD25+Foxp3+ regulatory T cells (Treg) and CD3+CD8-IL17A+ Th17 cells and the mean fluorescence intensities (MFI) of Foxp3 and IL-17 were measured at 1 week, 1 month, 3 months, 6 months, and 12 months after MSCs transplantation (MSCT). Serum cytokines, including transforming growth factor beta (TGF-ß), tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and IL-17A were detected using ELISA. Peripheral blood mononuclear cells from patients were collected and co-cultured with UC MSCs at ratios of 1:1, 10:1, and 50:1, respectively, for 72 h to detect the proportions of Treg and Th17 cells and the MFIs of Foxp3 and IL-17 were determined by flow cytometry. The cytokines in the supernatant solution were detected using ELISA. Inhibitors targeting TGF-ß, IL-6, indoleamine 2,3-dioxygenase (IDO), and prostaglandin E2 were added to the co-culture system, and the percentages of Treg and Th17 cells were observed. RESULTS: The percentage of peripheral Treg and Foxp3 MFI increased 1 week, 1 month, and 3 months after UC MSCs transplantation, while the Th17 proportion and MFI of IL-17 decreased 3 months, 6 months, and 12 months after the treatment, along with an increase in serum TGF-ß at 1 week, 3 months, and 12 months and a decrease in serum TNF-α beginning at 1 week. There were no alterations in serums IL-6 and IL-17A before or after MSCT. In vitro studies showed that the UC MSCs dose-dependently up-regulated peripheral Treg proportion in SLE patients, which was not depended on cell-cell contact. However, the down-regulation of Th17 cells was not dose-dependently and also not depended on cell-cell contact. Supernatant TGF-ß and IL-6 levels significantly increased, TNF-α significantly decreased, but IL-17A had no change after the co-culture. The addition of anti-TGF-ß antibody significantly abrogated the up-regulation of Treg, and the addition of PGE2 inhibitor significantly abrogated the down-regulation of Th17 cells. Both anti-IL-6 antibody and IDO inhibitor had no effects on Treg and Th17 cells. CONCLUSIONS: UC MSCs up-regulate Treg and down-regulate Th17 cells through the regulation of TGF-ß and PGE2 in lupus patients.

Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study.

The aim of this study is to assess the long-term safety of allogeneic umbilical cord mesenchymal stem cells (UC MSCs) transplantation for patients with refractory systemic lupus erythematosus (SLE). Nine SLE patients, who were refractory to steroid and immunosuppressive drugs treatment and underwent MSCs transplantation in 2009, were enrolled. One million allogeneic UC MSCs per kilogram of body weight were infused intravenously at days 0 and 7. The possible adverse events, including immediately after MSCs infusions, as well as the long-term safety profiles were observed. Blood and urine routine test, liver function, electrocardiogram, chest radiography and serum levels of tumor markers, including alpha fetal protein (AFP), cancer embryo antigen (CEA), carbohydrate antigen 155 (CA155) and CA199, were assayed before and 1, 2, 4 and 6 years after MSCs transplantation. All the patients completed two times of MSCs infusions. One patient had mild dizzy and warm sensation 5 min after MSCs infusion, and the symptoms disappeared quickly. No other adverse event, including fluster, headache, nausea or vomit, was observed. There was no change in peripheral white blood cell count, red blood cell count and platelet number in these patients after followed up for 6 years. Liver functional analysis showed that serum alanine aminotransferase, glutamic-oxalacetic transaminase, total bilirubin and direct bilirubin remained in normal range after MSCs infusions. No newly onset abnormality was detected on electrocardiogram and chest radiography. Moreover, we found no rise of serum tumor markers, including AFP, CEA, CA125 and CA199, before and 6 years after MSCs infusions. Our long-term observational study demonstrated a good safety profile of allogeneic UC MSCs in SLE patients.

Notch-1 knockdown suppresses proliferation, migration and metastasis of salivary adenoid cystic carcinoma cells.

BACKGROUND: Notch-1 promotes invasion and metastasis of cancer cells but its role in salivary adenoid cystic carcinoma (SACC) remains unelucidated. Here, we sought to investigate the effect of Notch-1 knockdown on the invasion and metastasis of SACC cells. METHODS: Stable ACC-M cells whose Notch-1 was silenced by lentiviral vectors were established. Cellular proliferation was evaluated by the MTT assays and clonogenic assays, apoptosis by flow cytometry and the migration of ACC-M cells by Transwell assays. Metastasis was evaluated by examining the number of lung nodules in Balb/c nu/nu nude mice bearing subcutaneous SACC xenografts. RESULTS: Our MTT assay revealed that Notch-1 knockdown significantly suppressed the proliferation of ACC-M cells compared with non-infected or scrambled control cells. Clonogenic assays further showed that Notch-1 knockdown significantly suppressed the clonogenic growth of ACC-M cells (p < 0.01 vs. controls). Our flow cytometry demonstrated that Notch-1 knockdown was associated with a significantly higher proportion of late apoptotic and necrotic cells (p < 0.01 vs. controls). Transwell assays revealed that Notch-1 knockdown markedly reduced the migratory capacity of ACC-M cells (p < 0.01 vs. controls) and xenograft studies showed that the number of metastatic nodules in the lung surface was significantly lower in nude mice bearing xenografts with Notch-1 knockdown compared to those bearing control xenografts (p < 0.01 vs. controls). CONCLUSION: Notch-1 knockdown suppresses the growth and migration of SACC cells in vitro and the metastasis of SACC cells in vivo. Notch-1 may be a new candidate target in SACC.